Author:Qingfeng Pharmaceutical Group
Posted Time:2024-12-12 00:00
On December 12, the bidding for the 10th batch of the National Organized Drug Centralized Procurement officially began. According to the "Public Announcement of the Proposed Selection Results for the National Drug Centralized Procurement" issued by the National Organization for Drug Procurement, 7 Qingfeng Pharmaceutical products were selected: XinKang® Lacosamide Injection, QingKaiSha® Rasagiline Mesylate Tablets, Zebixin® Mirabegron Sustained-release Tablets, Qingruike® Pregabalin Oral Solution, Zebeishu® Regorafenib Tablets, Qingkesha® Posaconazole Injection, and QingKeSha® Posaconazole Enteric-Coated Tablets.
In recent years, Qingfeng Pharmaceutical has actively responded to the country’s call for deepening healthcare system reforms, and has been actively participating in the centralized drug procurement process to ensure a stable supply of medications. The inclusion of these 7 products in the 10th batch of the National Centralized Drug Procurement initiative will further strengthen the company’s brand presence and improve the accessibility of these medications.
Moving forward, Qingfeng Pharmaceutical will improve production efficiency, strengthen the management of the full lifecycle of its medicines, and ensure the quality and market supply of the selected drugs. The company will continue to uphold its mission of "providing outstanding services for human health," focusing on unmet clinical needs, investing in research and development, and committed to producing high-quality, clinically valuable, and affordable medicines for patients.
